目的回顾性分析甘草酸二胺(第5组)、单胺(第6组)、山莨菪碱(第2组)、门冬氨酸钾镁(第3组)、山莨菪碱+门冬氨酸钾镁注射液(第4组)及口服茵黄片(第1组)治疗慢性乙型肝炎患者的疗效。方法慢性乙型肝炎1363例,甘草酸二胺150mg、单胺40ml、山莨菪碱10mg、门冬氨酸钾镁20ml分别加入5%~10%葡萄糖注射液250ml中静脉滴注,茵黄片口服,治疗结束后进行疗效分析。结果慢性乙型肝炎患者的临床治愈率为93.1%。5、6组患者的平均住院日、ALT复常时间为42.0、43.9,35.5、36.2天,较其他组缩短18~44、5~17.7天,较1、2组患者缩短7~9天,乏力、肝区叩痛消失时间为17.5、18.0,16.0、15.2天,较1、2、3组患者缩短5~8,9~12天,肝区不适消失时间为14.5、16.1天,较1组患者缩短16~18天(P<0.05~0.01)。结论在治疗慢性乙型肝炎时,甘草酸二胺、单胺在改善患者临床症状和肝功能指标方面优于茵黄片、山莨菪碱和门冬氨酸钾镁,该两种药物在治疗慢性乙型肝炎中疗效相当。口服茵黄片的疗效低于静脉应用药物。 Objective To retrospectively analyze the effects of glycyrrhizic acid diamine (group 5), monoamine (group 6), anisodamine (group 2), potassium and magnesium aspartate (group 3), anisodamine + Curative effect of potassium and magnesium injection (group 4) and oral Yinhuang tablets (group 1) in the treatment of chronic hepatitis B patients. Methods 1363 cases of chronic hepatitis B, glycyrrhizic acid diamine 150mg, monoamine 40ml, anisodamine 10mg, potassium magnesium aspartate 20ml were added 5% ~ 10% glucose injection 250ml intravenous infusion of Yinhuang tablets, After the end of treatment efficacy analysis. Results The clinical cure rate of patients with chronic hepatitis B was 93.1%. The mean length of stay of ALT in patients in groups 5 and 6 was 42.0, 43.9, 35.5 and 36.2 days, which was 18 to 44.5 to 17.7 days shorter than those in other groups, 7 to 9 days shorter than those in group 1 and 2 , The disappearance time of percussion pain in liver area was 17.5, 18.0, 16.0 and 15.2 days, shortened from 5 to 8 and 9 to 12 days in patients of group 1 and group 2, and the disappearance time of liver discomfort was 14.5 and 16.1 days, Shortened 16 to 18 days (P <0.05 ~ 0.01). Conclusions In the treatment of chronic hepatitis B, glycyrrhizic acid diamine and monoamine are superior to genistein, anisodamine and potassium magnesium aspartate in improving clinical symptoms and liver function of patients. The two drugs are effective in treating chronic hepatitis B Hepatitis in the same effect. The efficacy of Oral Huangpi tablets is lower than that of intravenous drugs.